All In Biotech

Drug Trial Radar · NCT07822477

A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV

A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

May 9, 2029

Study completion May 9, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV). This study will be conducted following the availability of initial safety and PK clinical data from formulation of the parent drug VH4524184.

Conditions

  • HIV Infections

Interventions

  • VH5356136 Formulation 1Drug

    Participants will receive VH5356136 Formulation 1 on Day 1.

  • VH5356136 Formulation 2Drug

    Participants will receive VH5356136 Formulation 2 on Day 1.

  • Placebo for VH5356136 Formulation 1Drug

    Participants will receive placebo for VH5356136 Formulation 1 on Day 1.

  • Placebo for VH5356136 Formulation 2Drug

    Participants will receive placebo for VH5356136 Formulation 2 on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with drug-related adverse events (AEs)Time frame: From Day 1 to Month 18
  2. Number of participants with Grade 2 to Grade 5 AEsTime frame: From Day 1 to Month 18
  3. Number of participants with serious adverse events (SAEs)Time frame: From Day 1 to Month 18
  4. Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  5. AUC(0-tlast) for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  6. Maximum plasma concentration (Cmax) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  7. Cmax for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  8. Time to maximum observed plasma drug concentration (tmax) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  9. Tmax for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  10. Terminal half-life (t1/2) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
  11. t1/2 for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.